Evaro, an NHS-licensed digital healthcare platform based in Norwich, has closed a $25m (£18m) Series A funding round.
Founded in 2018, Evaro provides embeddable digital pharmacy infrastructure and prescribing tools.
The company describes its model as “healthcare-as-a-service”, operating across three markets: Consumer brands looking to expand their revenue streams, healthcare providers looking to expand their digital capacity and employers, which can use the service as a form of staff health benefits.
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity,” said Evaro co-founder and chief executive Dr Thuria Wenbar.
“What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
AlbionVC led the Series A round with support also coming from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI.
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” said Christoph Ruedig, Partner at AlbionVC, who joins Evaro’s board.
“What sets Evaro apart is the depth of their regulatory stack. “Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials.
“This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”
